Expert Interview
A Second Look: Discussing the potential of Arrivent Biopharma's firmonertinib monotherapy and the ongoing phase 3 FURVENT study for first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC)
Ticker(s): AVBP, JNJInstiitution: USC
- Assistant Professor of Medicine in the division of Oncology at University of Southern California with a focus on thoracic cancers
- Manages roughly 5 Exon 20 insertation mutation NSCLC patients annually
- Research includes projects involving comprehensive genomic profiling looking at biomarkers in lung cancer, retrospective database work looking at lung cancer patients treated at USC looking at mutation differences among different ethnicities particularly Hispanics, epidemiological research looking at lung and thyroid cancer incorporating the California Cancer Registry, and translational research looking at tumor microenvironment and ethnicities in lung and breast cancer.
How accurate do you think prevalence/incidence estiamtes are for EGFR exon20 ins mutant NSCLC?
Added By: wilson_adminDoes firmonertinib have the potential to supplant Rybrevant + chemo?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
